Is Anemia in Preterm Infants Beneficial?

Preterm infants are at high risk for anemia—not because it is “good,” but because it is a common, clinically significant complication of prematurity. Anemia in this population refers to a hemoglobin concentration below age-appropriate reference thresholds—typically defined as less than 10–11 g/dL in the first few weeks of life, depending on gestational age and postnatal age.

This condition arises from multiple interrelated factors: rapid postnatal growth outpaces red blood cell production; frequent phlebotomy for laboratory testing contributes to iatrogenic blood loss; and immature erythropoiesis limits endogenous erythropoietin response and bone marrow output. Additionally, preterm infants have shorter red blood cell survival times compared with term infants.

Untreated or severe anemia can impair oxygen delivery to vital organs, potentially leading to tachycardia, tachypnea, poor feeding, apnea, bradycardia, and compromised neurodevelopmental outcomes. Therefore, clinicians closely monitor hemoglobin levels and assess clinical signs—not just lab values—to guide management.

Management strategies include minimizing diagnostic blood draws, optimizing iron supplementation (often starting at 2 mg/kg/day by 2 weeks of age), and reserving red blood cell transfusions for infants with symptomatic anemia or those at high risk for complications—such as extremely low birth weight infants with declining hemoglobin and cardiorespiratory instability. Recombinant human erythropoietin may be considered in select cases but is not routinely recommended due to modest efficacy and uncertain long-term benefit.

In summary, anemia in preterm infants is neither benign nor desirable—it is a pathophysiological consequence of developmental immaturity that requires vigilant monitoring and individualized, evidence-based intervention.